Clinical trial
A Study of Brivaracetam in Subjects With Partial Onset Seizures
NCT00175929 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00175929 |
|---|---|
| Title | A Study of Brivaracetam in Subjects With Partial Onset Seizures |
| Official title | A Multicenter, Double-blind, Randomized, Placebo-controlled, 3 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Ucb 34714 Used as Adjunctive Treatment at Doses of 50 and 150 mg/Day in b.i.d. Administration (Oral Capsules of 25 mg) for a Maximum of 12 Weeks in Subjects From… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Epilepsy, Focal |
| Intervention type | Drug, Other |
| Interventions | Placebo, Brivaracetam |
| Enrollment | 157 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Apr 13, 2015 |
| Countries | Belgium, Czechia, Finland, France, Germany, Netherlands, Poland, Spain, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: